Clinical trials: Sintilimab
Advanced Hepatocellular Carcinoma
Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma
An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
- Trial name
- NCT04401813
- Testing
- IBI308 200mg
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Colorectal Cancer
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common malignant tumor worldwide and the second leading cause of cancer-related deaths.
- Trial name
- NCT07398326
- Testing
- anlotinib and sintilimab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shanghai Changzheng Hospital
EBV-Positive DLBCL, Nos
Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
The prognosis of EBV+ DLBCL is dismal. Previous study showed that high level of PD-L1 expression in EBV+ DLBCL. The investigators therefore design this phase II study to investigate the safety and efficacy of sintilimab (an…
- Trial name
- NCT04181489
- Testing
- Sintilimab, Rituximab, Cyclophosphamide
- Where
- 11 sites in China
- Volunteers
- 55 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University